Cargando…
Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here we show that a single E2F cis-element mediates repression in normal cells and that expressio...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553775/ https://www.ncbi.nlm.nih.gov/pubmed/32985974 http://dx.doi.org/10.7554/eLife.61287 |
_version_ | 1783593671214497792 |
---|---|
author | Roelofs, Pieter A Goh, Chai Yeen Chua, Boon Haow Jarvis, Matthew C Stewart, Teneale A McCann, Jennifer L McDougle, Rebecca M Carpenter, Michael A Martens, John WM Span, Paul N Kappei, Dennis Harris, Reuben S |
author_facet | Roelofs, Pieter A Goh, Chai Yeen Chua, Boon Haow Jarvis, Matthew C Stewart, Teneale A McCann, Jennifer L McDougle, Rebecca M Carpenter, Michael A Martens, John WM Span, Paul N Kappei, Dennis Harris, Reuben S |
author_sort | Roelofs, Pieter A |
collection | PubMed |
description | APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous A3B gene. The same E2F site is required for A3B induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate the binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm the involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that A3B expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution. |
format | Online Article Text |
id | pubmed-7553775 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-75537752020-10-14 Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B Roelofs, Pieter A Goh, Chai Yeen Chua, Boon Haow Jarvis, Matthew C Stewart, Teneale A McCann, Jennifer L McDougle, Rebecca M Carpenter, Michael A Martens, John WM Span, Paul N Kappei, Dennis Harris, Reuben S eLife Cancer Biology APOBEC3B (A3B)-catalyzed DNA cytosine deamination contributes to the overall mutational landscape in breast cancer. Molecular mechanisms responsible for A3B upregulation in cancer are poorly understood. Here we show that a single E2F cis-element mediates repression in normal cells and that expression is activated by its mutational disruption in a reporter construct or the endogenous A3B gene. The same E2F site is required for A3B induction by polyomavirus T antigen indicating a shared molecular mechanism. Proteomic and biochemical experiments demonstrate the binding of wildtype but not mutant E2F promoters by repressive PRC1.6/E2F6 and DREAM/E2F4 complexes. Knockdown and overexpression studies confirm the involvement of these repressive complexes in regulating A3B expression. Altogether, these studies demonstrate that A3B expression is suppressed in normal cells by repressive E2F complexes and that viral or mutational disruption of this regulatory network triggers overexpression in breast cancer and provides fuel for tumor evolution. eLife Sciences Publications, Ltd 2020-09-28 /pmc/articles/PMC7553775/ /pubmed/32985974 http://dx.doi.org/10.7554/eLife.61287 Text en © 2020, Roelofs et al http://creativecommons.org/licenses/by/4.0/ http://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Cancer Biology Roelofs, Pieter A Goh, Chai Yeen Chua, Boon Haow Jarvis, Matthew C Stewart, Teneale A McCann, Jennifer L McDougle, Rebecca M Carpenter, Michael A Martens, John WM Span, Paul N Kappei, Dennis Harris, Reuben S Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B |
title | Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B |
title_full | Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B |
title_fullStr | Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B |
title_full_unstemmed | Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B |
title_short | Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B |
title_sort | characterization of the mechanism by which the rb/e2f pathway controls expression of the cancer genomic dna deaminase apobec3b |
topic | Cancer Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553775/ https://www.ncbi.nlm.nih.gov/pubmed/32985974 http://dx.doi.org/10.7554/eLife.61287 |
work_keys_str_mv | AT roelofspietera characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT gohchaiyeen characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT chuaboonhaow characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT jarvismatthewc characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT stewarttenealea characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT mccannjenniferl characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT mcdouglerebeccam characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT carpentermichaela characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT martensjohnwm characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT spanpauln characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT kappeidennis characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b AT harrisreubens characterizationofthemechanismbywhichtherbe2fpathwaycontrolsexpressionofthecancergenomicdnadeaminaseapobec3b |